Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 50, Issue 11, 2011, Pages 1129-1139.e2

  Froehlich, Tanya E ^a   Epstein, Jeffery N ^a   Nick, Todd G ^b   Melguizo Castro, Maria S ^b   Stein, Mark A ^c   Brinkman, William B ^a   Graham, Amanda J ^d   Langberg, Joshua M ^a   Kahn, Robert S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d DUQUESNE UNIVERSITY   (United States)

Author keywords

attention deficit hyperactivity disorder; dopamine transporter; methylphenidate; pharmacogenetics

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; PLACEBO;

3' UNTRANSLATED REGION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CODON; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EXON; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TEACHER; VANDERBILT ADHD RATING SCALE;

EID: 80054862518     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2011.08.002     Document Type: Article

References (76)

1. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108:1033-1044.
2. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180-187. (Pubitemid 32111021)
3. Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs. 2004;18:243-250. (Pubitemid 38393434)
4. Rapport MD, Stoner G, DuPaul GJ, Birmingham BK, Tucker S. Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior. J Abnorm Child Psychol. 1985;13:227-243. (Pubitemid 15053683)
5. Lowe N, Barry E, Gill M, Hawi Z. An overview of the pharmacogenetics and molecular genetics of ADHD. Curr Pharmacogenomics. 2006;4:231-243. (Pubitemid 44383179)
6. Polanczyk G, Zeni C, Genro JP, Roman T, Hutz MH, Rohde LA. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics. 2005;6:225-234. (Pubitemid 40601626)
7. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry. 2005;57:1367-1373. (Pubitemid 40798556)
8. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs. 2010;24:99-117.
9. Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin North Am. 2008;17:475-490, xi-xii. (Pubitemid 351265399)
10. Bellgrove MA, Hawi Z, Kirley A, Fitzgerald M, Gill M, Robertson IH. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology. 2005;30:2290-2297. (Pubitemid 41643982)
11. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(suppl 1):S31-S43.
12. Roman T, Rohde LA, Hutz MH. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit- hyperactivity disorder. Am J Pharmacogenomics. 2004;4:83-92. (Pubitemid 38560315)
13. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry. 1999;38:1474-1477.
14. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics. 2002; 12:497-499. (Pubitemid 34913533)
15. Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol. 2005;15:95-101.
16. Purper-Ouakil D, Wohl M, Orejarena S, et al. Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1425-1430.
17. Kirley A, Lowe N, Hawi Z, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet. 2003;121:50-54. (Pubitemid 37064030)
18. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30:1374-1382. (Pubitemid 40848091)
19. Joober R, Grizenko N, Sengupta S, et al. Dopamine transporter 3=-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology. 2007;32:1370-1376. (Pubitemid 46788847)
20. McGough JJ, McCracken JT, Loo SK, et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyper-activity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48: 1155-1164.
21. Langley K, Turic D, Peirce TR, et al. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet. 2005;139:7-10. (Pubitemid 41552288)
22. van der Meulen EM, Bakker SC, Pauls DL, et al. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child Psychol Psychiatry. 2005;46:1074-1080. (Pubitemid 44192653)
23. Bellgrove MA, Barry E, Johnson KA, et al. Spatial attentional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD. Neuropsychopharmacology. 2008;33:2536-2545.
24. Zeni CP, Guimaraes AP, Polanczyk GV, et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/ hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144:391-394. (Pubitemid 46646664)
25. Kereszturi E, Tarnok Z, Bognar E, et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1431-1435.
26. Tharoor H, Lobos EA, Todd RD, Reiersen AM. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:527-530. (Pubitemid 351830816)
27. Heckers S, Konradi C. Synaptic function and biochemical neuroanatomy. In: Martin A, Scahill L, Charney DS, Leckman JF, eds. Pediatric Psychopharmacology: Principles and Practice. New York: Oxford University Press; 2003:20-32.
28. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57: 1313-1323. (Pubitemid 40798551)
29. Seeger G, Schloss P, Schmidt MH. Marker gene polymorphisms in hyperkinetic disorder-predictors of clinical response to treatment with methylphenidate? Neurosci Lett. 2001;313:45-48. (Pubitemid 32973891)
30. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyper-activity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol. 2004;14:564-574.
31. Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ. Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry. 2000;5:396-404. (Pubitemid 30455953)
32. McGough J, McCracken J, Swanson J, et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1314-1322. (Pubitemid 44665448)
33. Cheon KA, Kim BN, Cho SC. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology. 2007;32:1377-1383.
34. Nestler EJ, Hyman SE, Malenka RC. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. New York: McGraw-Hill; 2001.
35. Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet. 1997;51: 129-130. (Pubitemid 27149724)
36. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64:218- 224.
37. da Silva TL, Pianca TG, Roman T, et al. Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm. 2008;115:341-345.
38. Cheon KA, Cho DY, Koo MS, Song DH, Namkoong K. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyper-activity disorder. Biol Psychiatry. 2009;65:564-570.
39. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250. (Pubitemid 26226317)
40. Cheon KA, Jun JY, Cho DY. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. Int Clin Psychopharmacol. 2008;23:291-298.
41. Polanczyk G, Faraone SV, Bau CH, et al. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1419-1424.
42. Kieling C, Genro JP, Hutz MH, Rohde LA. A current update on ADHD pharmacogenomics. Pharmacogenomics. 2010;11:407- 419.
43. Froehlich TE, Stein MA. Pharmacogenomics of ADHD. In: Schwab M, Kaschka W, Spina E, eds. Pharmacogenomics in Psychiatry. Basel: Karger Medical and Scientific Publishers; 2010.
44. Yang L, Wang YF, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004;43:1154-1158. (Pubitemid 39096873)
45. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
46. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry. 2000;39:28-38. (Pubitemid 30029897)
47. Wolraich ML, Feurer ID, Hannah JN, Baumgaertel A, Pinnock TY. Obtaining systematic teacher reports of disruptive behavior disorders utilizing DSM-IV. J Abnorm Child Psychol. 1998;26:141-152. (Pubitemid 28249061)
48. Wolraich ML, Lambert W, Doffing MA, Bickman L, Simmons T, Worley K. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol. 2003;28:559-567. (Pubitemid 37449138)
49. Wolraich ML, Lambert EW, Bickman L, Simmons T, Doffing MA, Worley KA. Assessing the impact of parent and teacher agreement on diagnosing attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004;25:41-47. (Pubitemid 38263286)
50. Malhi P, Singhi P, Sidhu M. Impact of parent and teacher concordance on diagnosing attention deficit hyperactivity disorder and its sub-types. Indian J Pediatr. 2008;75:223-228. (Pubitemid 351712985)
51. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:1025-1032.
52. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404.
53. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics. 1991;87:519-531.
54. Gorman EB, Klorman R, Thatcher JE, Borgstedt AD. Effects of methylphenidate on subtypes of attention-deficit/hyper-activity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:808-816. (Pubitemid 43932907)
55. Laird N. Further comparative analyses of prettest-posttest research designs. Am Stat. 1983;37:329-330.
56. Barkley RA. Predicting the response of hyperkinetic children to stimulant drugs: a review. J Abnorm Child Psychol. 1976;4:327-348. (Pubitemid 8019377)
57. Arnold LE, Elliot M, Sachs L, et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol. 2003;71:713-727. (Pubitemid 36897405)
58. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc. 2005;97(suppl):11S-16S. (Pubitemid 41429050)
59. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied Regression Analysis and Other Multivariable Methods. 3rd ed. Pacific Grove, CA: Brooks/Cole Publishing Company; 1998.
60. Gilbert DL, Wang Z, Sallee FR, et al. Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain. 2006;129(Pt 8):2038-2046. (Pubitemid 44289069)
61. Schoots O, Van Tol HH. The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J. 2003;3:343-348. (Pubitemid 38072172)
62. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. 1995; 65:1157-1165.
63. Jovanovic V, Guan HC, Van Tol HH. Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants. Pharmacogenetics. 1999;9:561-568.
64. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science. 1977;198:1274-1276. (Pubitemid 8308550)
65. Rowe DC, Stever C, Giedinghagen LN, et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol Psychiatry. 1998;3:419-426. (Pubitemid 28442415)
66. Todd RD, Huang H, Smalley SL, et al. Collaborative analysis of DRD4 and DAT genotypes in population-defined ADHD subtypes. J Child Psychol Psychiatry. 2005;46:1067-1073. (Pubitemid 44192652)
67. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH. Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/ hyperactivity disorder? Am J Med Genet B Neuropsychiatr Genet. 2003;120:116-120. (Pubitemid 37059387)
68. Roman T, Polanczyk GV, Zeni C, Genro JP, Rohde LA, Hutz MH. Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. Mol Psychiatry. 2006;11: 8-10. (Pubitemid 43251082)
69. Park L, Nigg JT, Waldman ID, et al. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry. 2005;10:572-580. (Pubitemid 40897041)
70. Comings DE, Gade-Andavolu R, Gonzalez N, Blake H, Wu S, MacMurray JP. Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin Genet. 1999;55:160-172. (Pubitemid 29178733)
71. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1412-1418.
72. Graetz BW, Sawyer MG, Baghurst P. Gender differences among children with DSM-IV ADHD in Australia. J Am Acad Child Adolesc Psychiatry. 2005;44:159-168. (Pubitemid 40189827)
73. Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of U.S. children. Arch Pediatr Adolesc Med. 2007;161:857-864. (Pubitemid 47360887)
74. Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319-324. (Pubitemid 26072289)
75. Gaub M, Carlson CL. Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. J Abnorm Child Psychol. 1997;25:103-111. (Pubitemid 27169353)
76. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry. 1995; 34:629-638.